Bevacizumab and rapamycin inhibit tumor growth in peritoneal model of human ovarian cancer

Molecular Cancer Therapeutics

Volumn 6, Issue 11, 2007, Pages 2959-2966

  Huynh, Hung ^a   Teo, Ching Ching Melissa ^b   Khee, Chee Soo ^a,b  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CYCLIN D1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN P70; RAPAMYCIN; S6 KINASE; VASCULOTROPIN RECEPTOR;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER MODEL; CANCER PREVENTION; CANCER SURVIVAL; CELL PROLIFERATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DENSITY; FEMALE; MICROVASCULATURE; MONOTHERAPY; MOUSE; NONHUMAN; OVARY CARCINOMA; PERITONEUM; PERITONEUM CANCER; PERITONEUM METASTASIS; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ASCITES; BODY WEIGHT; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MICE; MICE, SCID; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; SIROLIMUS; TUMOR BURDEN;

EID: 36749068988     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-0237     Document Type: Article

References (40)

1. Boocock CA, Charnock-Jones DS, Sharkey AM, et al. Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst 1995;87:506-16.
2. Runowicz CD, Fields AL, Goldberg GL. Promising new therapies in the treatment of advanced ovarian cancer. Cancer 1995;76:2028-33.
3. Bando E, Yonemura Y, Takeshita Y, et al. Intraoperative lavage for cytological examination in 1,297 patients with gastric carcinoma. Am J Surg 1999;178:256-62.
4. Smith EM, Jayson GC. The current and future management of malignant ascites. Clin Oncol (R Coll Radiol) 2003;15:59-72.
5. Hasumi Y, Mizukami H, Urabe M, et al. Soluble FLT-1 expression suppresses carcinomatous ascites in nude mice bearing ovarian cancer. Cancer Res 2002;62:2019-23.
6. Graves LE, Ariztia EV, Navari JR, Matzel HJ, Stack MS, Fishman DA. Proinvasive properties of ovarian cancer ascites-derived membrane vesicles. Cancer Res 2004;64:7045-9.
7. Willemse PH, De Vries EG. Intraperitoneal chemotherapy for ovarian cancer: a question of feasibility? Drug Resist Updat 2003;6:165-7.
8. Geisinger KR, Berens ME, Duckett Y, Morgan TM, Kute TE, Welander CE. The effects of estrogen, progesterone, and tamoxifen alone and in combination with cytotoxic agents against human ovarian carcinoma in vitro. Cancer 1990;65:1055-61.
9. Vasey PA, Atkinson R, Coleman R. Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer. Br J Cancer 2001;84:170-8.
10. Sandercock J, Parmar MK, Torri V, Qian W. First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence. Br J Cancer 2002;87:815-24.
11. Armstrong DK, Bundy B, Wenzel L. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34-43.
12. Johnston SRD. Ovarian Cancer: review of the National Institute for Clinical Excellence (NICE) guidance recommendations. Cancer Invest 2004;22:730-42.
13. Liu J, Yang G, Thompson-Lanza JA, et al. A genetically defined model for human ovarian cancer. Cancer Res 2004;64:1655-63.
14. Mutch DG, Williams S. Biology of epithelial ovarian cancer. Clin Obstet Gynecol 1994;37:406-22.
15. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995;146:1029-39.
16. Paley PJ, Staskus KA, Gebhard K, et al. Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 1997;80:98-106.
17. Hu L, Hofmann J, Jaffe RB. Phosphatidylinositol 3-kinase mediates angiogenesis and vascular permeability associated with ovarian carcinoma. Clin Cancer Res 2005;11:8208-12.
18. Pourgholami MH, Yan CZ, Lu Y, Wang L, Morris DL. Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice. Clin Cancer Res 2006;12:1928-35.
19. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501.
20. Shayesteh L, Lu Y, Kuo WL, et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999;21:99-102.
21. Easton JB, Houghton PJ. mTOR and cancer therapy. Oncogene 2006;25:6436-46.
22. Wong AS, Kim SO, Leung PC, Auersperg N, Pelech SL. Profiling of protein kinases in the neoplastic transformation of human ovarian surface epithelium. Gynecol Oncol 2001;82:305-11.
23. Fingar DC, Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 2004;23:3151-71.
24. Treins C, Giorgetti-Peraldi S, Murdaca J, Semenza GL, Van Obberghen E. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. J Biol Chem 2002;277:27975-81.
25. Luan FL, Hojo M, Maluccio M, Yamaji K, Suthanthiran M. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation 2002;73:1565-72.
26. Hojo M, Morimoto T, Maluccio M. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999;397:530-4.
27. Huynh H, Soo KC, Chow PK, Panasci L, Tran E. Xenografts of human hepatocellular carcinoma: a useful model for testing drugs. Clin Cancer Res 2006;12:4306-14.
28. Tallarida RJ. Drug synergism: its detection and applications. J Pharmacol Exp Ther 2001;298:865-72.
29. Duarte I, Llanos O. Patterns of metastases in intestinal and diffuse types of carcinoma of the stomach. Hum Pathol 1981;12:237-42.
30. Maehara Y, Moriguchi S, Kakeji Y, et al. Pertinent risk factors and gastric carcinoma with synchronous peritoneal dissemination or liver metastasis. Surgery 1991;110:820-3.
31. Takahashi I, Matsusaka T, Onohara T, et al. Clinicopathological features of long-term survivors of scirrhous gastric cancer. Hepatogastroenterology 2000;47:1485-8.
32. Hudson CC, Liu M, Chiang GG, et al. Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002;22:7004-14.
33. Yang SX, Chen JH, Jiang XF, et al. Activation of chemokine receptor CXCR4 in malignant glioma cells promotes the production of vascular endothelial growth factor. Biochem Biophys Res Commun 2005;335:523-8.
34. Bachelder RE, Wendt MA, Mercurio AM. Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. Cancer Res 2002;62:7203-6.
35. Kryczek I, Lange A, Mottram P, et al. CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res 2005;65:465-72.
36. Schioppa T, Uranchimeg B, Saccani A, et al. Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med 2003;198:1391-402.
37. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002;8:128-35.
38. Luan FL, Ding R, Sharma VK, Chon WJ, Lagman M, Suthanthiran M. Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int 2003;63:917-26.
39. Garrison RN, Kaelin LD, Galloway RH, Heuser LS. Malignant ascites. Clinical and experimental observations. Ann Surg 1986;203:644-51.
40. Marincola FM, Schwartzentruber DJ. Malignant ascites. 5th ed. In: DeVita VT, Hellman J, Rosenberg SA, editors. Cancer: principles and practice of oncology. Philadelphia: Lippincott-Raven; 1997. p. 2598-606.